Navigation Links
Dr. Charles Sanders to Become Lead Director of Epiphany Biosciences
Date:10/2/2008

SAN FRANCISCO, Oct. 2 /PRNewswire-FirstCall/ -- Epiphany Biosciences, Inc. announced today that Dr. Charles Sanders has accepted the position of Lead Director. Dr. Sanders is a highly experienced biotechnology and pharmaceutical executive, currently serving as Lead Director of Genentech. He has also served as chief executive officer of Glaxo Inc., from 1989-1994 and chairman of the board from 1992-1995. In addition, Dr. Sanders is also a member of the Boards of Directors of Vertex Pharmaceuticals, Cephalon, Inc., and Icagen, Inc.

"The Epiphany strategy of addressing long-term disease as sequelae of chronic viral infection offers a unique perspective in addressing unmet medical needs in a variety of patients. Dr. Volinsky has assembled an outstanding team and I am happy to work with them to reach their goals," reported Dr. Sanders.

"We are elated to have Dr. Sanders as our Lead Director. His extensive experience in the biotechnology industry has already helped propel Epiphany forward and we look forward to his continued input and counsel," stated Fred Volinsky, MD, the Chief Executive Officer of Epiphany Biosciences.

"Next year will be a critically important time for the company as we plan to collect data from up to four Phase 2 studies as well as continue further development of our HCV pipeline," commented Brian Murphy, MD, Chief Medical Officer of Epiphany. "Dr. Sanders' guidance will be very valuable at this pivotal time."

About Epiphany Biosciences:

Epiphany Biosciences is a privately-held company developing therapeutic products and diagnostic technologies that treat or help prevent the spread of pathogenic viruses, including varicella virus (VZV), Epstein-Barr Virus (EBV) and hepatitis C virus (HCV).

Contact:

Fred Volinsky

CEO of Epiphany Biosciences, Inc.

+1-415-765-7193


'/>"/>
SOURCE Epiphany Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Charles C. Harwood, Jr., Joins Cellectar, Inc.s Board of Directors
2. Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at The Association for Research in Vision and Ophthalmology
3. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
4. Dr. Charles A. Sims of California Cryobanks Family Cord Blood Services Named to National Stem Cell Advisory Council
5. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
6. Informed Medical Communications Appoints Charles T. Saldarini to Board of Directors
7. Leading Lobbying Firm Celebrates Growth and New Name: Troutman Sanders Strategies
8. Squire Sanders Stands Out in Independent Analysis of Law Firms in Europe
9. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
10. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
11. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... (PRWEB) , ... May 20, 2016 , ... Korean researchers ... that it may offer a new way to treat the disease. Surviving Mesothelioma has ... now. , Scientists from several Korean institutions based their mesothelioma study on the ...
(Date:5/19/2016)... Ashland, Virginia (PRWEB) , ... May 19, 2016 , ... ... a new 30,000 square foot office building is complete. The new structure adds a ... In 2011, Anton Paar USA purchased 2.4 acres of land, along with ...
(Date:5/19/2016)... -- There is no saying when exactly ... pressures in pricing and lack in consumer confidence. One ... - numerous opportunities are up for grabs but this ... four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: ... VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/19/2016)... May 19, 2016 ... (OTC PINK: RGBPP) announced today initiation of a ... cord blood based cancer immunotherapeutic product leveraging its ... Regen described a generation of cord blood derived ... gene silencing.  The product in development will be ...
Breaking Biology Technology:
(Date:3/15/2016)... -- Yissum Research Development Company of the Hebrew ... Hebrew University, announced today the formation of Neteera ... human biological indicators. Neteera Technologies has completed its first ... ... emissions from sweat ducts, enables reliable and speedy biometric ...
(Date:3/10/2016)... India , March 10, 2016 ... a new market research report "Identity and Access Management ... & Audit, Compliance, and Governance), by Organization Size, by ... to 2020", published by MarketsandMarkets, The market is estimated ... USD 12.78 Billion by 2020, at a Compound Annual ...
(Date:3/8/2016)... , March 8, 2016   Valencell ... technology, today announced it has secured $11M in ... GII Tech, a new venture fund being launched ... additional participation from existing investors TDF Ventures and ... funds to continue its triple-digit growth and accelerate ...
Breaking Biology News(10 mins):